Heart failure treatment co Magenta Medical raises $4m

Pitango is investing $4 million in the entrepreneurs who sold Ventor Technologies to Medtronic for $325 millon.

Magenta Medical, which develops novel devices for the treatment of acute and chronic heart failure, has raised $4 million from Pitango Venture Capital.

The company was founded just two months ago by Prof. Ehud Schwammenthal and Yosi Tuval. In 2004, these two entrepreneurs founded Ventor Technologies, a former Pitango portfolio company, which developed an innovative catheter-based system for the minimally invasive replacement of the aortic valve. Medtronic Inc. acquired Ventor for $325 million in 2009.

Magenta's founders are reluctant to reveal details about their new enterprise but Schwammenthal told "Globes," "“Magenta was founded on the premise that CHF can be managed using a device that does not underestimate the complexity and the inter-patient variability of the disease." Pitango partner Dr. David Israeli who joins the board of Magenta said, "We chose to invest in the company, among other things because the entrepreneurs succeeded in the past. But we have not made any allowances for that when examining the idea and its maturity. The idea is very impressive and the market has vast potential."

Published by Globes [online], Israel business news - www.globes-online.com - on December 3, 2012

© Copyright of Globes Publisher Itonut (1983) Ltd. 2012

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters גלובס